Possible 先駆け審査指定制度対象品目の募集 against 株式会社 ヘリオス
For developers: integration details
You do not need this for normal browsing. Use it when integrating this enforcement record into an internal tool or AI workflow.
/api/v1/enforcements?company=%E6%A0%AA%E5%BC%8F%E4%BC%9A%E7%A4%BE%20%E3%83%98%E3%83%AA%E3%82%AA%E3%82%B9&limit=10Action summary
- Company
- 株式会社 ヘリオスJapanese originalOriginal: 株式会社 ヘリオス
- Entity match
- Possible entity match60/100Machine extractedCompany name extracted from the Japanese public disclosure
- Governing law
- 薬事法薬事法
- Action type
- 先駆け審査指定制度対象品目の募集先駆け審査指定制度対象品目の募集
- Action date
- 5 October 2017
- Issuing authority
- Ministry of Health, Labour and Welfare厚生労働省
Violation
Human (same species) adult bone marrow-derived pluripotent precursor cells for acute phase cerebral infarction (18 to 36 hours after onset)
Show original Japanese text
ヒト（同種）成人骨髄由来多能性前駆細胞 脳梗塞急性期（発症後18～36時間）
Compliance context
Context neededThis is a public Japanese regulatory disclosure. The exact legal effect depends on the cited source and regulator.
Japanese regulatory disclosure under 薬事法.
Review the original Japanese source and determine relevance to your counterparty-risk workflow.
This context is an operational aid for review workflows, not a credit opinion or legal conclusion.
Evidence pack
- Extracted at
- 2026-04-24T23:38:31.322+00:00
- Evidence checked
- 2026-04-24T23:38:31.322+00:00
- Archive captured
- 2026-04-03T10:22:01.646+00:00
Show audit JSON
{
"record": {
"id": "be65330f-d8fa-41f7-92f6-7084595d318d",
"url": "https://regbase.jp/en/enforcement/other-heriosu-20171005",
"company_name_original": "株式会社 ヘリオス",
"company_name_registry": "株式会社 ヘリオス",
"corporate_number": null,
"law": {
"ja": "薬事法",
"en": "薬事法"
},
"action_type": {
"ja": "先駆け審査指定制度対象品目の募集",
"en": "先駆け審査指定制度対象品目の募集"
},
"authority": {
"ja": "厚生労働省",
"en": "Ministry of Health, Labour and Welfare"
}
},
"entity_match": {
"status": "possible",
"confidence": 60,
"method": "extracted_japanese_name",
"method_label": "Company name extracted from the Japanese public disclosure",
"notes": null
},
"review": {
"status": "unreviewed",
"label": "Machine extracted"
},
"compliance_context": {
"severity": "Context needed",
"actionMeaning": "This is a public Japanese regulatory disclosure. The exact legal effect depends on the cited source and regulator.",
"practicalNote": "Review the original Japanese source and determine relevance to your counterparty-risk workflow.",
"lawContext": "Japanese regulatory disclosure under 薬事法."
},
"evidence": {
"recordUrl": "https://regbase.jp/en/enforcement/other-heriosu-20171005",
"officialSourceUrl": "https://www.mhlw.go.jp/stf/houdou/0000179802.html",
"archiveUrl": "https://kiroku.today/view/ceb343f564ir7hxe",
"archiveCapturedAt": "2026-04-03T10:22:01.646+00:00",
"extractedAt": "2026-04-24T23:38:31.322+00:00",
"translatedAt": "2026-05-01T06:52:30.414+00:00",
"evidenceCheckedAt": "2026-04-24T23:38:31.322+00:00",
"generatedAt": "2026-06-19T11:42:37.934Z"
},
"limitations": [
"RegBase aggregates public Japanese government disclosures and does not provide a credit opinion.",
"English summaries are provided for reference. The original Japanese source is authoritative.",
"Possible or unresolved entity matches should be manually verified before use in a decision."
]
}The original Japanese disclosure is the authoritative record. Use possible or unresolved matches only as leads for manual review.
Language
日本語版を見る (Japanese)About this recordAggregated and translated from public Japanese government disclosures. The English text is for reference only — authoritative content is the linked Japanese source.